Arrowhead Pharmaceuticals
Update in progressARWR (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Arrowhead Pharmaceuticals, Inc. develops RNA interference therapies for hard‑to‑treat diseases in the United States. Its pipeline includes Plozasiran (APO C‑III) in Phase 3, Zodasiran (ANGPTL3) in Phase 3, ARO‑DIMER‑PA (dual RNAi) in Phase 1/2a, and ARO‑PNPLA3 in Phase 1. It also has ARO‑INHBE, ARO‑ALK7, ARO‑RAGE, ARO‑MAPT, ARO‑C3, and ARO‑CFB in various early phases. The company collaborates with GSK, Takeda, Amgen, and Sarepta. Founded 2003, Pasadena, California.
Company score
- Sentiment
- 2.24
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 1.37
- Governance
- 0.51
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.52
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 1.38
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Loading section